ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Brinzolamide microsponge-loaded in situ gel for sustained ocular delivery: design, characterization and in vivo evaluation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, brinzolamide (BRZ) -an anti-glaucoma drug was formulated into microsponge-loaded in situ gel for improved ophthalmic delivery. Microsponges were developed using solvent emulsion diffusion method comprising Eudragit RL-100. Further, microsponges integrated into in situ gel to provide longer residence into eyes. Various formulation and process parameters affecting microsponge characteristics were optimized. Amongst different formulations, S14 formulation with 2:1 drug-polymer ratio showed highest entrapment efficiency (93%), smallest particle size 10.3 μm and polydispersity index 0.22, useful for ocular delivery. Further, S14 batch was embedded into in situ gel comprising poloxamer 407 and poloxamer 188 in combination (ISG I) and poloxamer 407 alone (ISG II). In situ gel was assessed for various physicochemical and rheological properties. Biological tests like HET-CAM assay, corneal irritation test and in vivo efficacy study were performed to assess suitability for ocular delivery. In vivo studies revealed that both ISG I and ISG II exhibited superior therapeutic efficacy (achieved grater reduction in intraocular pressure) and were non-irritant to rabbit eyes. The sustained drug release and improved ocular properties reflect that ISG I and ISG II have the capability to improve glaucoma treatment. To conclude, BRZ microsponge-loaded in situ gel puts forward possible, effective alternate delivery system for effective glaucoma management.
Indexed as
Identifiers
42012658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.